Suppr超能文献

紫杉醇纳米粒的细胞内自组装克服多药耐药性。

Intracellular Self-Assembly of Taxol Nanoparticles for Overcoming Multidrug Resistance.

机构信息

CAS Key Laboratory of Soft Matter Chemistry, Department of Chemistry, University of Science and Technology of China, 96 Jinzhai Road, Hefei, Anhui 230026 (China) http://lianglab.ustc.edu.cn.

School of Life Sciences, University of Science and Technology of China, Hefei, Anhui 230027 (China).

出版信息

Angew Chem Int Ed Engl. 2015 Aug 10;54(33):9700-4. doi: 10.1002/anie.201504329. Epub 2015 Jun 26.

Abstract

Multidrug resistance (MDR) remains the biggest challenge in treating cancers. Herein we propose the intracellular self-assembly of nanodrugs as a new strategy for overcoming MDR. By employing a biocompatible condensation reaction, we rationally designed a taxol derivative Ac-Arg-Val-Arg-Arg-Cys(StBu)-Lys(taxol)-2-cyanobenzothiazole (CBT-Taxol) which could be subjected to furin-controlled condensation and self-assembly of taxol nanoparticles (Taxol-NPs). In vitro and in vivo studies indicated that, compared with taxol, CBT-Taxol showed a 4.5-fold or 1.5-fold increase in anti-MDR effects, respectively, on taxol-resistant HCT 116 cancer cells or tumors without being toxic to the cells or the mice. Our results demonstrate that structuring protease-susceptible agents and assembling them intracellularly into nanodrugs could be a new optimal strategy for overcoming MDR.

摘要

多药耐药(MDR)仍然是癌症治疗的最大挑战。在此,我们提出了纳米药物的细胞内自组装作为克服 MDR 的一种新策略。通过采用生物相容性的缩合反应,我们合理设计了一种紫杉醇衍生物 Ac-Arg-Val-Arg-Arg-Cys(StBu)-Lys(紫杉醇)-2-氰基苯并噻唑(CBT-紫杉醇),它可以受到弗林蛋白酶控制的缩合和紫杉醇纳米颗粒(Taxol-NPs)的自组装。体外和体内研究表明,与紫杉醇相比,CBT-紫杉醇对紫杉醇耐药的 HCT116 癌细胞或肿瘤的抗 MDR 作用分别增加了 4.5 倍或 1.5 倍,而对细胞或小鼠没有毒性。我们的结果表明,将蛋白酶敏感剂构建并在细胞内组装成纳米药物可能是克服 MDR 的一种新的最佳策略。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验